Compare FUN & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FUN | VRDN |
|---|---|---|
| Founded | 1983 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 2023 | 2014 |
| Metric | FUN | VRDN |
|---|---|---|
| Price | $10.04 | $30.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 17 |
| Target Price | $14.23 | ★ $41.69 |
| AVG Volume (30 Days) | ★ 6.8M | 2.8M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | ★ 11.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,100,289,000.00 | $5,706,000.00 |
| Revenue This Year | N/A | $6.01 |
| Revenue Next Year | $3.55 | $316.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 14.45 | N/A |
| 52 Week Low | $6.60 | $13.18 |
| 52 Week High | $26.28 | $34.29 |
| Indicator | FUN | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 55.12 | 82.22 |
| Support Level | $6.60 | $17.84 |
| Resistance Level | $12.39 | N/A |
| Average True Range (ATR) | 0.70 | 1.47 |
| MACD | 0.53 | 0.75 |
| Stochastic Oscillator | 77.87 | 98.56 |
Six Flags Entertainment Corp is North America's regional amusement resort operator with approximately 27 amusement parks, around 15 separately gated water parks, and nine resort properties across the U.S., Canada, and Mexico. It provides coasters, themed rides, thrilling water parks, resorts, and a portfolio of beloved intellectual properties such as Looney Tunes, DC Comics, and PEANUTS. The parks are family-oriented, with recreational facilities for people of all ages, and provide clean and attractive environments with exciting rides and immersive entertainment. The Company generates revenue from sales of admission to the amusement parks and water parks, from purchases of food, merchandise and games both inside and outside the parks, from the sale of accommodations and other extra-charge.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.